Restricted accessResearch articleFirst published online 2021-8
Exposure to serotonin selective reuptake inhibitors or serotonin noradrenaline reuptake inhibitors and sexual dysfunction: Results from an online survey
Post-SSRI Sexual Dysfunction (PSSD) is characterized by sexual and emotional symptoms associated to the exposure to Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Noradrenaline Reuptake Inhibitors (SNRI).
OBJECTIVE:
The present study provides a comprehensive picture on demographic and clinical characteristics associated to PSSD.
METHODS:
An online survey was run on subjects self-declaring as affected by PSSD. The survey collected socio-demographic and clinical data via questions created ad hoc and three standardized scales (Arizona Sexual Experiences Scale, Hospital Anxiety and Depression Scale, World Health Organization Wellbeing Index).
RESULTS:
A total of 135 subjects (115 males; mean age 31.9 ± 8.9 years) was analysed. The syndrome was more represented among young, heterosexual males after the exposure to SSRI/SNRI at relatively high doses. The major findings involved the temporal sequence of symptoms: 118 subjects had symptoms both during and after SSRI/SNRI administration, and 17 only after, thus deposing for a iatrogenic action of SSRI/SNRI. Different variables, represented by both emotional and sexual symptoms, accounted for the variability of the severity of the sexual dysfunction as well as of wellbeing.
CONCLUSIONS:
Based on the present results, PSSD is a complex iatrogenic syndrome in need of being further studied and understood.
CarvalhoAFSharmaMSBrunoniARVietaEFavaGA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: A critical review of the literature. Psychother Psychosom. 2016;85:270–88.
2.
FavaGARafanelliC. Iatrogenic factors in psychopathology. Psychother Psychosom. 2019;88:129–40.
3.
BahrickA. Persistence of sexual dysfunction side effects after discontinuation of antidepressant medications: Emerging evidence. Open Psychol J. 2008;1:42–50.
4.
CsokaABShipkoS. Persistent sexual side effects after SSRI discontinuation. Psychother Psychosom. 2006;75(3):187–8.
5.
BahrickA. Post SSRI sexual dysfunction. Am Soc Adv Pharmacother Tab. 2006;7:2–3, 10-1.
6.
BalaANguyenHMTHellstromWJ. Post-SSRI sexual dysfunction: A literature review. Sex Med Rev. 2018;6:29–34.
7.
HealyD. Citizen petition: Sexual side effects of SSRIs and SNRIs. Int J Risk Saf Med. 2018;29:135–47.
8.
CsokaABahrickAMehtonenOP. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. J Sex Med. 2008;5(1):227–33.
9.
ReismanY. Sexual consequences of post-SSRI syndrome. Sex Med Rev. 2017;5(4):429–33.
10.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: Author; 2013.
11.
PatacchiniACosciF , A paradigmatic case of post selective serotonin reuptake inhibitors sexual dysfunction or withdrawal after discontinuation of selective serotonin reuptake inhibitors? J Clin Psychopharmacol. 2020;40(1):93–5.
12.
CosciFChouinardG. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020;7:1–24.
13.
HealyDLe NouryJManginD. Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. Int J Risk Saf Med. 2018;29:125–34.
14.
Ben-SheetritJAizenbergDCsokaABWeizmanAHermeshH. Post-SSRI sexual dysfunction: Clinical characterization and preliminary assessment of contributory factors and dose-response relationship. J Clin Psychopharmacol. 2015;35(3):273–8.
15.
McGahueyAGelenbergAJCinC. The Arizona Sexual Experience Scale (ASEX): Reliability and validity. J Sex Marital Ther. 2000;26:25–40.
16.
ZigmondASSnaithRP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361–70.
17.
WHO. Wellbeing Measures in Primary Health Care/The Depcare Project. Copenhagen: WHO Regional Office for Europe; 1998.
18.
SoykanA. The reliability and validity of Arizona sexual experiences scale in Turkish ESRD patients undergoing hemodialysis. Int J Impot Res. 2004;16:531–4.
19.
JitkritsadakulOJagotaPBhidayasiriR. The Arizona Sexual Experiences Scale: A validity and reliability assessment of the Thai translation (ASEX-Thai) in Parkinson’s disease. J Park Dis. 2014;4:205–10.
20.
BjellandIDahlAAHaugTTNeckelmannD. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52:69–77.
21.
BlomEHBechPHogbergGLarssonJOSerlachiusE. Screening for depressed mood in an adolescent psychiatric context by brief selfassessment scales: Testing psychometric validity of WHO-5 and BDI-6 indices by latent trait analyses. Health Qual Life Out. 2012;10:149.
22.
Lucas-CarrascoRAllerupPBechP. The validity of the WHO-5 as an early screening for apathy in an elderly population. Curr Gerontol Geriatr Res. 2012;171857.
23.
ToppCWØstergaardSDSøndergaardSBechP. The WHO-5 Wellbeing Index: A systematic review of the literature. Psychother Psychosom. 2015;84:167–76.
24.
BonsignoreMBarkowKJessenFHeunR. Validity of the five-item WHO Wellbeing Index (WHO-5) in an elderly population. Eur Arch Psychiatr Clin Neurosci. 2001;251:27–31.
25.
KimHY. Statistical notes for clinical researchers: Chi-squared test and Fisher’s exact test. Restor Dent Endod. 2017;42(2):152–5.
26.
TerraccianoAMcCraeRRCostaPT. Factorial and construct validity of the Italian Positive and Negative Affect Schedule (PANAS). Eur J Psychol Assess. 2003;19:131–41.
27.
RothmanKJ. No adjustments are needed for multiple comparisons. Epidemiol. 1990;1(1):43–6.
28.
StephensonCPKarangesEMcGregorIS. Trends in the utilization of psychotropic medications in Australia from 2000 to 2011. Aust NZJ Psychiatry. 2013;47(1):74–87.
29.
WaldingerMDvan CoevordenRSSchweitzerDHGeorgiadisJ. Penile anesthesia in Post SSRI Sexual Dysfunction (PSSD) responds to low-power laser irradiation: A case study and hypothesis about the role of transient receptor potential (TRP) ion channels. Eur J Pharmacol. 2015;753:263–8.
30.
HoganCLe NouryJHealyDManginD. One hundred and twenty cases of enduring sexual dysfunction following treatment. Int J Risk Saf Med. 2014;26:109–16.
FavaGA , Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry. 2003;64:123–33.
33.
FavaGACosciF. Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. J Clin Psychiatry. 2019;80(6), 19com12794.
34.
CalabròRSDe LucaRManuliAPortaroSNaroAQuattriniF. Towards improving Post-SSRI sexual dysfunction by using nutriceuticals: Lessons from a case study. J Sex Mar Ther. 2019;45(6):562–5.
35.
LaurentSMSimonsAD. Sexual dysfunction in depression and anxiety: Conceptualizing sexual dysfunction as part of an internalizing dimension. Clin Psychol Rev. 2009;29:573–85.
36.
ThorlowDKAndersonROddoneE. Cascade iatrogenesis: Factors leading to the development of adverse events in hospitalized older adults. Int J Nurs Stud. 2009;46(11):1528–35.
37.
FavaGABelaiseC. Discontinuing antidepressant drugs: Lesson from a failed trial and extensive clinical experience. Psychother Psychosom. 2018;87(5):257–67.
38.
ColemanJAGreenEMGouauxE. X-ray structures and mechanism of the human serotonin transporter. Nature. 2016;532(7599):334–9.
39.
ShapiroBB. Subtherapeutic doses of SSRI antidepressants demonstrate considerable serotonin transporter occupancy: Implications for tapering SSRIs. Psychopharmacol. 2018;235(9):2779–81.
40.
HorwitzRISingerBH. Why evidence-based medicine failed in patient care and medicine-based evidence will succeed. J Clin Epidemiol. 2017;84:14–7.
41.
LobitzGArmstrongKConcatoJSingerBHHorwitzR. The biological and biographical basis of precision medicine. Psychother Psychosom. 2019;88(6):333–40.
